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gust 26, 2013.he study sought to determine the prognostic importance of left atrial (LA) dilation in patients with type 2 diabetes
mellitus (T2DM) and no history of cardiovascular disease (CVD).Background T2DM is associated with the development of CVD, and morphological changes in the heart may appear before
symptoms arise.Methods A total of 305 T2DM patients without known CVD referred to a diabetes clinic were included consecutively (age
58.6  11.3 years, diabetes duration 2.0 [interquartile range: 0 to 6.0] years). Each patient underwent
a comprehensive echocardiogram and a myocardial perfusion scintigraphy (MPS) at inclusion. Patients were
divided according to left atrial volume index (LAVi) 32 ml/m2. Patients were followed for median of 5.6
(interquartile range: 5.1 to 6.1) years for the occurrence of major cardiac events and death.Results LAVi 32 ml/m2 was found in 105 patients (34%). During follow-up, 60 patients (20%) experienced the composite
endpoint, of whom 28 (9%) died. Patients with LAVi 32 ml/m2 had a signiﬁcantly higher cardiac event rate and
death rate (p < 0.001 and p ¼ 0.002, respectively). Univariate predictors of the composite endpoint were age,
hypertension, left ventricular diastolic function, E/e0septum-ratio and LAVi 32 ml/m2; however, myocardial ischemia
on MPS was not a predictor. When adjusting for age and hypertension, only LAVi 32 ml/m2 was a predictor of the
composite endpoint (hazard ratio: 1.82 [95% conﬁdence interval: 1.08 to 3.07], p ¼ 0.024).Conclusions Increased LAViwas an independent and incremental predictor of cardiovascularmorbidity andmortality in T2DMpatients
with no history of CVD. (Presence of Macrovascular Disease in Type 2 Diabetes Mellitus; NCT00298844). (J Am Coll
Cardiol 2013;62:2416–21)ª 2013 by the American College of Cardiology FoundationThe morbidity (1,2) and mortality (3) of type 2 diabetes
mellitus (T2DM) is closely associated with development of
cardiovascular disease (CVD). In T2DM, morphological
changes suggestive of heart disease may appear before
symptoms arise. The prevalence of left ventricular (LV)
diastolic dysfunction has been shown to be increased among
T2DM patients (4) and, further, to also predict outcome (5).
The evaluation of diastolic function requires multiple
Doppler echocardiography variables (6). As these variables
are inﬂuenced by pre- and after-load, they will reﬂect the
instantaneous interaction of LV ﬁlling pressures and LVlogy, Odense University Hospital, Odense,
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; revised manuscript received August 16, 2013,compliance (7). During ventricular diastole, left atrial (LA)
and LV pressures will equalize. Factors causing LV ﬁlling
pressure to rise will, therefore, also cause LA pressure
overload and LA dilation (7,8). Thus, in the absence of LA
volume overload, LA volume will reﬂect both the severity
and duration of LV diastolic dysfunction (6,8,9). In agree-
ment with this, LA size has proven to be a powerful predictor
of outcome in several disease entities, including myocardial
infarction, severe aortic valve stenosis, andheart failure (10–12).
The importance of LA dilation in T2DM patients is, how-
ever, not known. On the basis of this, we hypothesized that left
atrial volume index (LAVi) would predict long-term outcome
in these patients.
Methods
Study group. The present single-center study has previ-
ously been described in detail (13). In brief, 431 consecutive
T2DM patients without any medical history of CVD met
the inclusion and exclusion criteria, of whom 126 declined
participation; thus, 305 (71%) patients were enrolled after
Abbreviations
and Acronyms
CVD = cardiovascular
disease
LAVi = left atrial volume
index
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MACE = major
cardiovascular event(s)
MPS = myocardial perfusion
scintigraphy
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mellitus
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2417providing informed consent. The study was registered at
www.clinicaltrials.gov (NCT00298844) and was approved by
the local ethics committee.
Each patient underwent a single-day structured examination
program including an echocardiogram, myocardial perfusion
scintigraphy (MPS), and 1-point 51Cr-EDTA clearance
procedure.
Echocardiography. The echocardiograms were obtained on
a Vivid 5 GE medical ultrasound machine with a 2.5 MHz
transducer (GE Medical System, Horten, Norway). Blinded
analysis of images was done using EchoPac 7.0, PC-08 (GE
Medical System, Horten, Norway). For all Doppler and
tissue Doppler recordings, a horizontal sweep of 100 mm/s
was used, and the average of 5 consecutive beats was
measured and averaged.
LV SYSTOLIC FUNCTION. LV ejection fraction and LV
volumes were estimated using the biplane modiﬁed Simp-
son’s method (14). LV dimensions were obtained from the
parasternal long-axis view (14).
LV DIASTOLIC FUNCTION. Mitral inﬂow was assessed with
pulsed-wave Doppler obtained with the transducer in the
apical 4-chamber view, with the Doppler beam aligned
perpendicular to the plane of the mitral annulus. The
Doppler sample volume was placed between the tips of the
mitral leaﬂets during diastole. Pulsed-wave tissue Doppler
was used at the septal and lateral mitral annulus to measure
the mitral plane movement. LV ﬁlling was divided into 4
distinct ﬁlling patterns (normal, impaired relaxation, pseu-
donormal, and restrictive ﬁlling) on the basis of a combina-
tion of mitral inﬂow and tissue Doppler measurements of
the mitral plane movement (6).
LAVI. LAVi was estimated by the biplane area-length method,
using measurements at the apical 4- and 2-chamber views at
end-systole and indexed by body surface area (14). LAVi 32
ml/m2 was considered abnormally increased. The absolute
interobserver agreement between 2 observers obtained in 20
randomly-selected study patients on LV diastolic ﬁlling pattern
andLAVi over or below 32ml/m2was 95% (kappa¼ 0.91) and
85% (kappa ¼ 0.70), respectively.
MPS. MPS examinations were performed using electrocar-
diogram-gated single photon emission computed tomog-
raphy with 99mtechnetium sestamibi. Whenever a potential
stress-induced perfusion defect was observed, an additional
rest study was carried out to evaluate the degree of revers-
ibility. A semiquantitative visual interpretation was made by
2 observers using a 20-segment model. A summed stress
score (SSS) was calculated. Myocardial ischemia was deﬁned
as a regional perfusion abnormality with a total SSS 4 and
at least 1 segment with an SSS 2. The diagnostic accuracy
has been reported previously (15).
Clinical follow-up. The primary endpoint was a composite
endpoint of death from all causes or the appearance of the
ﬁrst-occurred cardiovascular event during follow-up. Major
adverse cardiovascular events (MACE) were nonfatalmyocardial infarction, unstable
angina, acute heart failure, is-
chemic stroke, and coronary or
peripheral revascularization using
the criteria from the DIAD (De-
tection of Ischemia in Asymp-
tomatic Diabetics) trial (16). The
secondary endpoint was death
from all causes.
Overall mortality and MACE
were recorded from the Danish
Personnel Register and from
discharge notes available in the
Danish Admission Registry on
October 1, 2012. In case of am-
biguous information, original patient charts were reviewed.
Statistics. Continuous variables are presented asmean SD
and variables with a non-Gaussian distribution as median
(interquartile range). Categorical variables are presented as
numbers and percentages. The Student t test and Mann-
Whitney 2-sample tests were used to test for between-group
differences in independent continuous parametric and
nonparametric variables. The chi-square test was used to test
for differences between categorical variables.
Overall mortality and event rates were calculated using the
product limit method and presented in Kaplan-Meier plots.
Event rates were compared using the log-rank test. Further,
estimation of hazard ratios was performed using Cox
proportional hazards models. Comparison of each model’s
predictive capability was performed by comparing the C-
statistic derived from the area under the receiver-operating
characteristic curves using the generalized U statistic. A
p value <0.05 was considered signiﬁcant using STATA/SE
12.0 (StataCorp, College Station, Texas).Results
The study included 305 consecutive T2DM patients who
were followed for a median 5.6 (5.1 to 6.1) years, with
complete follow-up data for all patients. Patient and echo-
cardiographic characteristics are presented in Tables 1 and 2.
During follow-up, 60 patients (20%) experienced the
composite endpoint, and 41 (15%) experienced a MACE.
At follow-up, patients with LAVi 32 ml/m2 had signiﬁ-
cant higher event rates (p < 0.001) (Fig. 1). Finally, during
follow-up 28 patients (9%) died (Table 3), and further
patients with LAVi 32 ml/m2 had lower overall survival
(p ¼ 0.002) (Fig. 1). Finally, the 5-year event rates increased
with increasing LAVi (Fig. 2). Univariate and multivariate
predictors of the composite endpoint are presented in
Table 4. When adjusting for age and hypertension, only
LAVi 32 ml/m2 was a predictor of the composite
endpoint (Table 4). Finally, the incremental value of LAVi
assessed in 4 modeling steps is shown in Figure 3. The
addition of LAVi 32 ml/m2 increased the area under the
Table 1 Patient Characteristics
Total
(n ¼ 305)
LAVi <32 ml/m2
(n ¼ 200)
LAVi 32 ml/m2
(n ¼ 105) p Value
Age, yrs 58.6  11.3 56.3  11.4 63.0  9.9 <0.001
Male 166 (54) 107 (54) 59 (56) 0.655
Diabetes duration, yrs 2 (0–7) 2 (0–6) 3 (0–9) 0.307
BMI, kg/m2 32.2  5.8 32.4  5.8 31.9  5.9 0.519
Blood pressure, systolic, mm Hg 138.7  18.1 136.5  17.4 142.7  18.9 0.004
Blood pressure, diastolic, mm Hg 79.5  10.9 78.9  10.2 80.5  12.2 0.217
HbA1c, % 7.3  1.3 7.4  1.4 7.1  1.1 0.081
Fasting C-peptide concentration, pmol/l 1,028 (721–1,402) 979 (694–1,393) 1109 (788–1,453) 0.091
Fasting insulin concentration, pmol/l 76 (46–114) 77 (45–116) 75 (48–113) 0.682
Total cholesterol concentration, pmol/l 4.4  1.0 4.4  1.1 4.3  1.0 0.136
LDL cholesterol concentration, pmol/l 2.2  0.8 2.2  0.8 2.0  0.8 0.039
HDL cholesterol concentration, pmol/l 1.28  0.34 1.26  0.34 1.31  0.36 0.184
Creatinine, mmol/l 90  24 87  18 96  33 0.001
GFR, ml/min/m2 89.6  23.0 92.3  22.3 84.3  23.4 0.004
Hypertension 197 (64) 121 (61) 75 (71) 0.058
Hypercholesterolemia 193 (63) 119 (60) 74 (70) 0.059
Current smoker 82 (27) 64 (32) 17 (16) 0.003
Atrial ﬁbrillation 12 (4) 3 (2) 9 (9) 0.003
Values are mean  SD, n (%), or median (interquartile range) Glomerular ﬁltration rate (GFR) was measured by the 1-point 51Cr-EDTA clearance
procedure.
BMI ¼ body mass index; HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density lipoprotein; LAVi ¼ left atrial volume index; LDL ¼ low-density
lipoprotein.
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diabetes duration, hypertension, and age (p ¼ 0.02).
Myocardial ischemia demonstrated on MPS was not
a univariate predictor of the composite endpoint. WhenTable 2 Echocardiographic Characteristics
Total
(n ¼ 305)
Echocardiography
Systolic function
LV ejection fraction, % 59.8  7.2
S’septum, cm/s 7.9  1.3
S’lateral, cm/s 8.5  1.7
Diastolic function and grade
Peak E-wave velocity, m/s 0.80  0.16
Peak A-wave velocity, m/s 0.85  0.19
E/A ratio 0.96  0.25
DT, ms 220  48
Vp, cm/s 52.0  16.9
e’septum, cm/s 8.3  1.9
e’lateral, cm/s 10.5  1.7
E/e’septum-ratio 10.0  2.7
LA volume index, ml/m2 28.8  7.4
Normal LV diastolic function 184 (60)
Grade 1 LV diastolic dysfunction 67 (22)
Grade 2 LV diastolic dysfunction 54 (18)
Grade 3 LV diastolic dysfunction 0
LV mass index,* g/m2 98.8  21.0
Myocardial perfusion scintigraphy
Myocardial ischemia 92 (30)
Values are mean SD or n (%). *LV mass index was calculated using the follo
surface area (14).
DT ¼ deceleration time; LAVi ¼ left atrial volume index; LV ¼ left ventricadjusting for myocardial ischemia in a multivariate Cox
regression analysis, LAVi 32 ml/m2 was still a predictor of
the composite endpoint (hazard ratio: 2.46 [95% conﬁdence
interval: 1.47 to 4.14], p ¼ 0.001).LAVi <32 ml/m2
(n ¼ 200)
LAVi 32 ml/m2
(n ¼ 105) p Value
60.8  6.1 57.9  8.7 <0.001
8.1  1.1 7.4  1.4 <0.001
8.6  1.7 8.2  1.9 0.028
0.80  0.16 0.80  0.16 0.751
0.82  0.17 0.92  0.22 <0.001
1.00  0.23 0.88  0.26 <0.001
216  42 226  55 0.060
55.7  15.2 43.6  16.2 <0.001
8.9  1.7 7.1  1.7 <0.001
10.7  2.5 9.6  2.6 <0.001
9.2  2.0 11.7  3.0 <0.001
24.9  3.9 37.5  4.9 <0.001
162 (81) 22 (17) <0.001
38 (19) 29 (27) 0.056
1 (1) 53 (51) <0.001
0 0
94.9  18.5 106.8  23.4 <0.001
48 (24) 44 (46) 0.001
wing formula: (0.8(1.04(LVDdþIVSdþPWd)3(LVDd)3))þ0.6g)/body
ular; Vp ¼ propagation velocity.
Figure 1 Survival
Survival from the composite endpoint and overall survival. LAVi ¼ left atrial volume index.
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The present prospective observational follow-up study of
T2DM patients without overt CVD at inclusion demon-
strated that a dilated LA was associated with increased
morbidity and mortality independent of other important
risk factors. Thus, a dilated LA proved in T2DM to be
a morphological change associated with increased cardiovas-
cular risk.
As the LA in absence of LA volume overload will dilate
secondary to increased LA afterload, increased LV ﬁlling
pressure and decreased LV chamber compliance are believed
to be important predictors of LA dilation in the present
population. Although the present study does not offer insight
into the mechanism causing LA pressure overload, it seems
plausible that there exists a link between T2DM and diastolicTable 3
Overall Mortality or Cardiovascular Events at
Follow-Up
Clinical Outcome
Total
(n ¼ 305)
LAVi <32 ml/m2
(n ¼ 200)
LAVi 32 ml/m2
(n ¼ 105)
Mortality 28 11 17
Cardiovascular event
Acute myocardial
infarction
6 (2) 3 (2) 3 (3)
Unstable angina 6 (2) 3 (2) 3 (3)
PCI 9 (3) 4 (2) 5 (5)
CABG 4 (1) 2 (1) 2 (2)
Acute heart failure 3 (1) 1 (1) 2 (2)
Ischemic stroke 11 (4) 5 (3) 6 (6)
Peripheral
revascularization
2 (1) 0 (0) 2 (2)
Values are n (%). Cardiovascular event is deﬁned as the ﬁrst-occurred cardiovascular event during
follow-up.
CABG ¼ coronary artery bypass grafting; LAVi ¼ left atrial volume index; PCI ¼ percutaneous
coronary intervention.dysfunction rather than assuming that this is a coincidental
association. A decrease in LV compliance in T2DM patients
may be caused by microvascular disease, altered myocardial
metabolism, and structural changes in the myocardium with
increased ﬁbrosis. Some evidence is emerging on the role of
myocardial lipotoxic injury from lipid oversupply. Visceral
adipose tissue insulin resistance leads to increased myocardial
fatty acid delivery and uptake in the myocardium, with asso-
ciated myocardial triglyceride accumulation (17,18). It has
been suggested that accumulation of fatty acid intermediates
is associated with mitochondrial dysfunction, leading to cell
damage, replacement with ﬁbrosis, and decreased myocar-
dial compliance (18).Figure 2 5-Year Event Rates
Unadjusted 5-year event rates of the composite endpoint in 6 equal groups
according to left atrial volume index (LAVi).
Table 4 Univariate and Multivariate Predictors of the Composite Endpoint of Overall Mortality or Cardiovascular Event
Univariable Multivariable
Hazard Ratio 95% Conﬁdence Interval p Value Hazard Ratio 95% Conﬁdence Interval p Value
Age, yrs 1.07 1.04–1.10 <0.001
Diabetes duration, yrs 1.04 1.00–1.09 0.054 1.00 0.95–1.04 0.946
HbA1c, % 2.35 0.38–14.5 0.360 3.63 0.41–32.1 0.246
Hypertension 2.33 1.24–4.41 0.009
Atrial ﬁbrillation 1.93 0.70–5.34 0.203 1.17 0.42–3.28 0.764
Myocardial ischemia 1.32 0.78–2.25 0.297
LV systolic function
LV ejection fraction <50% 2.01 0.92–4.45 0.081 2.76 1.23–6.17 0.013
s’septum 0.93 0.76–1.14 0.487 1.01 0.82–1.25 0.898
s’lateral 1.00 0.86–1.16 0.976 1.00 0.86–1.17 0.949
LV diastolic function
Grade 0 0.51 0.31–0.85 0.010 0.86 0.50–1.48 0.580
Grade 1 1.91 1.12–3.26 0.017 1.14 0.64–2.02 0.662
Grade 2 1.26 0.67–2.37 0.473 1.06 0.56–1.99 0.866
E/e’septum >15 3.33 1.51–7.33 0.003 1.90 0.84–4.29 0.121
LAVi 32 ml/m2 2.51 1.51–4.17 <0.001 1.82 1.08–3.07 0.024
In the multivariate Cox proportional hazards analysis each outcome variable was adjusted for age and hypertension. Myocardial ischemia was demonstrated on myocardial perfusion scintigraphy.
LV ¼ left ventricular; other abbreviations as in Table 1.
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of death and MACE, even after adjustment for age
and hypertension. Further, we could demonstrate that
LAVi predicted cardiovascular morbidity and mortalityFigure 3 Left Atrial Volume Index
Incremental value of assessment of left atrial volume index (LAVi) 32 ml/m2
in predicting the composite endpoint.independently of myocardial ischemia. This is in agreement
with the DIAD trial, where MPS-detected myocardial
ischemia proved not to be a predictor of outcome in T2DM
patients without CVD during a follow-up of 4.8 years (16).
There are several possible explanations why increased
LAVi can predict long-term outcome. First, LA volume
reﬂects both the severity and duration of increased LA and
LV ﬁlling pressure (7,8), whereas Doppler assessment of LV
diastolic function only reﬂects the beat-to-beat interaction
of LV ﬁlling pressures and LV compliance (7). Therefore,
the LAVi may be a better prognostic parameter as compar-
ed with assessment of LV diastolic function. Second,
abnormal diastolic function is characterized by a dispropor-
tional increase of LV ﬁlling pressure to maintain cardiac
output especially during exercise (19), and these hemody-
namic abnormalities caused by diastolic dysfunction are
believed to drive the progression from an asymptomatic
stage to symptomatic heart failure. Thus, the LAVi may
be considered a morphological link between the asymp-
tomatic and symptomatic stage.
Study limitations. Despite great effort, almost one-third of
eligible patients refused to participate in the study. Although
no statistical differences were present between the study
group and the nonparticipants with regard to age and dia-
betes duration (data not shown), selection bias cannot be
ruled out.Conclusions
In T2DM patients without known CVD, increased LAVi
was associated with worse overall survival and increased risk
of MACE including myocardial infarction and ischemic
stroke. Further, the prognostic value of LAVi persisted after
adjusting for age and hypertension. Therefore, measurement
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2421of LAVi could emerge as a simple and important tool for
risk stratiﬁcation in T2DM patients.
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